

Nur für Forschungszwecke

VPRBP Monoklonaler Antikörper

Katalog-Nr.:66392-1-Ig

Vorgestelltes Produkt

1 Publikationen



Allgemeine Informationen

Katalog-Nr.: 66392-1-Ig	GenBank-Zugangsnummer: BC022792	Reinigungsmethode: Protein-A-Reinigung
Größe: 150ul , Konzentration: 2500 µg/ml von9730 Nanodrop und 2000 µg/ml durch die Bradford-Methode mit BSA als Standard;	GeneID (NCBI): Vollständiger Name: Vpr (HIV-1) binding protein	CloneNo.: 1A7A8
Wirt: Maus	Berechnete Masse: 1506 aa, 169 kDa	Empfohlene Verdünnungen: WB 1:1000-1:4000 IHC 1:50-1:500 IF 1:200-1:800
Isotyp: IgG2a	Beobachtete Masse: 169 kDa	
Immunogen Katalognummer: AG2184		

Anwendungen

Geprüfte Anwendungen: IF, IHC, WB, ELISA	Positivkontrollen: WB : HepG2-Zellen, DU 145-Zellen, HEK-293-Zellen, HeLa-Zellen, K-562-Zellen, PC-3-Zellen
In Publikationen genannte Anwendungen: WB	IHC : humanes Mammakarzinomgewebe, IF : humanes Mammakarzinomgewebe,
Getestete Reaktivität: Human	
Zitierte Arten: Human, Maus	
Hinweis-IHC: Antigenmaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigenmaskierung auch mit Citratpuffer pH 6,0 erfolgen.	

Hintergrundinformationen

VprBP was first identified as a protein that can interact with HIV-1 viral protein R (PMID: 11223251). It is a component of the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex that could interact with HIV-1 virus Vpr protein and HIV-2 virus Vpx protein (PMID: 18332868; 17314515; 18606781). VprBP is a 1,507-amino acid protein that contains conserved domains, including YXXY repeats, the Lis homology motif, and WD40 repeats. Through binding to Vpr, VprBP allows Vpr to modulate the catalytic activity of the CUL4-DDB1 complex, which in turn leads to the induction of G2 phase arrest in the virus-infected cells (PMID: 17630831). Recently it has been reported that VprBP is able to regulate the p53-induced transcription and apoptotic pathway (PMID: 22184063).

Bemerkenswerte Veröffentlichungen

Verfasser	Pubmed ID	Journal	Anwendung
Nikhil B Ghate	37069142	Nat Commun	WB

Lagerung


Lagerungsbedingungen:
Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil
Lagerungspuffer:
PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
Aliquotieren ist nicht notwendig bei -20°C Lagerung

*** 20ul-Größen enthalten 0.1% BSA


For technical support and original validation data for this product please contact:
T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA)
E: proteintech@ptglab.com
W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.


Ausgewählte Validierungsdaten




Various lysates were subjected to SDS PAGE followed by western blot with 66392-1-Ig (VPRBP antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.




WB result of VPRBP antibody (66392-1-Ig; 1:1000; incubated at room temperature for 1.5 hours) with sh-Control and sh-VPRBP transfected HEK-293 cells.




Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 66392-1-Ig (VPRBP antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 66392-1-Ig (VPRBP antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using VPRBP antibody (66392-1-Ig, Clone: 1A7A8) at dilution of 1:400 and CoraLite@488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



Immunofluorescent analysis of (4% PFA) fixed human breast cancer tissue using VPRBP antibody (66392-1-Ig, Clone: 1A7A8) at dilution of 1:400 and CoraLite@488-Conjugated AffiniPure Goat Anti-Mouse IgG(H+L).